Depression in schizophrenia: recognition and management in the USA

Siris, Samuel G.; Addington, Donald; Azorin, Jean‐Michel; Falloon, Ian R. H.; Gerlach, Jes; Hirsch, Steven R.

doi:10.1016/s0920-9964(00)00135-3

Cited by 122 publications

(79 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As previously stated, there exists a high incidence of comorbidity of depressive symptoms in patients with schizophrenia (Siris et al, 2001), and there is mounting evidence to support the value of SRI augmentation in the treatment of the negative symptoms of schizophrenia (Silver, 2003;Mazeh et al, 2004). Therefore, doses of WS-50030 that were active in rat conditioned avoidance and increased extracellular 5-HT were evaluated in a preclinical model of depression, specifically the olfactory bulbectomy-induced hyperactivity model in rats.…”

Section: Discussionmentioning

confidence: 99%

“…In addition to the positive, negative, and cognitive symptoms of schizophrenia, there exists a high incidence of comorbidity of depressive symptoms in patients with schizophrenia (Siris et al, 2001). Serotonin reuptake inhibitors (SRIs) are commonly used in the clinic to treat both depression and anxiety, and there is mounting evidence to support the value of SRI augmentation in the treatment of the negative symptoms of schizophrenia (Silver, 2003;Mazeh et al, 2004).…”

mentioning

confidence: 99%

See 1 more Smart Citation

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: A Novel Dopamine D₂ Receptor Partial Agonist/Serotonin Reuptake Inhibitor with Preclinical Antipsychotic-Like and Antidepressant-Like Activity

Brennan¹,

Graf²,

Grauer³

et al. 2009

J Pharmacol Exp Ther

View full text Add to dashboard Cite

The preclinical characterization of propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one] is described. In vitro binding and functional studies revealed highest affinity to the D 2 receptor (D 2L K i , 4.0 nM) and serotonin transporter (K i , 7.1 nM), potent D 2 partial agonist activity (EC 50 , 0.38 nM; E max , 30%), and complete block of the serotonin transporter (IC 50 , 56.4 nM). Consistent with this in vitro profile, WS-50030 (10 mg/kg/day, 21 days) significantly increased extracellular 5-HT in the rat medial prefrontal cortex, short-term WS-50030 treatment blocked apomorphine-induced climbing (ID 50 , 0.51 mg/kg) in a dose range that produced minimal catalepsy in mice and induced low levels of contralateral rotation in rats with unilateral substantia nigra 6-hydroxydopamine lesions (10 mg/kg i.p.), a behavioral profile similar to that of the D 2 partial agonist aripiprazole. In a rat model predictive of antipsychotic-like activity, WS-50030 and aripiprazole reduced conditioned avoidance responding by 42 and 55% at 10 mg/kg, respectively. Despite aripiprazole's reported lack of effect on serotonin transporters, long-term treatment with aripiprazole or WS-50030 reversed olfactory bulbectomy-induced hyperactivity at doses that did not reduce activity in sham-operated rats, indicating antidepressant-like activity for both compounds. Despite possessing serotonin reuptake inhibitory activity in addition to D 2 receptor partial agonism, WS-50030 displays activity in preclinical models predictive of antipsychotic-and antidepressant efficacy similar to aripiprazole, suggesting potential efficacy of WS-50030 versus positive and negative symptoms of schizophrenia, comorbid mood symptoms, bipolar disorder, major depressive disorder, and treatment-resistant depression. Furthermore, WS-50030 provides a tool to further explore how combining these mechanisms might differentiate from other antipsychotics or antidepressants.Schizophrenia is a debilitating disease that affects approximately 1% of the world population. The symptoms of schizophrenia can be loosely categorized into three main groups: positive symptoms, such as hallucinations and delusions; negative symptoms, such as social withdrawal and anhedo- Article, publication date, and citation information can be found at http://jpet.aspetjournals.org. doi:10.1124/jpet.109.157388.ABBREVIATIONS: SRI, serotonin reuptake inhibitor; 6-OHDA, 6-hydroxydopamine; propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one; WAY-100635, N-[2-[4-(2-methoxyphenyl)

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: A Novel Dopamine D₂ Receptor Partial Agonist/Serotonin Reuptake Inhibitor with Preclinical Antipsychotic-Like and Antidepressant-Like Activity

Brennan¹,

Graf²,

Grauer³

et al. 2009

J Pharmacol Exp Ther

View full text Add to dashboard Cite

show abstract

“…Su búsqueda se basó en su correlación con las enfermedades concomitantes reportadas con mayor riesgo de esquizofrenia o de estados psicóticos (8)(9)(10)(11)(12)(13)(14)(15)(16).…”

Section: Materiales Y Métodosunclassified

“…Se han identificado algunas enfermedades concomitantes más comunes en pacientes con trastorno esquizofrénico, tales como la depresión (la cual puede tener una prevalencia de 25,0 %) (8), los trastornos de ansiedad (4,0-51,0 %) (9,10), la diabetes mellitus (7,9 %) (11), la dislipidemia (8,2 %) (12), el VIH/sida (4,0 %) (13), el déficit de atención e hiperactividad (17,0 %) (14), la enfermedad de Parkinson (riesgo de 3,1 veces mayor) (15) e infarto agudo de miocardio (riesgo 1,8 veces mayor en pacientes esquizofrénicos) (16).…”

unclassified

Patrones de prescripción de antipsicóticos en pacientes afiliados al Sistema de Seguridad Social en Salud de Colombia

Machado‐Alba

Morales-Plaza

2013

biomedica

View full text Add to dashboard Cite

Introducción. La esquizofrenia altera la percepción del individuo, el pensamiento, el afecto y el comportamiento. El tratamiento farmacológico puede mejorar estas manifestaciones. Objetivo. Determinar los patrones de prescripción de medicamentos antipsicóticos en un grupo de pacientes afilados al Sistema General de Seguridad Social en Salud de Colombia. Materiales y métodos. Se llevó a cabo un estudio descriptivo sobre base de datos de 6,2 millones de personas. Se seleccionaron los pacientes medicados con antipsicóticos, de ambos sexos, todas las edades, con tratamiento continuo de marzo a junio de 2012, y residentes de 57 ciudades colombianas. Se diseñó una base de datos sobre consumo de medicamentos, obtenidos por la empresa que dispensa dichos fármacos. Resultados. Se estudiaron 3.075 pacientes con edad promedio de 55,8±21,5 años; 50,3 % eran mujeres; 81,9 % recibían monoterapia y, 18,1 %, dos o más antipsicóticos. El orden de prescripción fue: atípicos, 77,1 %, y clásicos, 31,9 %. Los medicamentos más utilizados fueron: quetiapina (30,3 %), clozapina (23,7 %), levomepropamiza (18,4 %) y risperidona (14,9 %). Las combinaciones más frecuentes fueron: haloperidol más levomepromazina (n=67; 12,1 % de las asociaciones), clozapina más pipotiazina (n=54; 9,7 %) clozapina más risperidona (n=45; 8,1 %), quetiapina más levomepromazina (n=40; 7,2 %). Los medicamentos prescritos concomitantemente más frecuentes fueron: antidepresivos (n=998; 32,5 %); ansiolíticos (n=799; 26,0 %); hipolipemiantes (n=672; 21,9 %); antiparkinsonianos (341; 11,1 %) y antidiabéticos (n=327; 10,6 %). Conclusiones. Predominan los hábitos de prescripción de medicamentos de alto valor terapéutico, principalmente en la monoterapia antipsicótica. En la mayoría, se emplean en dosis superiores a las recomendadas. Se plantea la necesidad de diseñar estrategias educativas para corregir algunos hábitos de prescripción e investigaciones que evalúen la efectividad del tratamiento.Palabras clave: esquizofrenia, prescripciones de medicamentos, antipsicóticos, clozapina, haloperidol, farmacoepidemiología, Colombia. doi: http://dx.doi.org/10.7705/biomedica.v33i3.1529 Antipsychotic prescription patterns in patients affiliated to the Social Security Health System in ColombiaIntroduction: Schizophrenia alters individual perception, thought, affection and behavior. Drug therapy can improve these manifestations. Objective: To determine prescription patterns of antipsychotic drugs in a group of patients affiliated to the Social Security Health System in Colombia. Materials and methods:This was a descriptive study with a 6.2 million people database. We selected 3,075 patients medicated with antipsychotics, of both sexes, and all ages, with continuous treatment from March to June, 2012, and residing in 57 Colombian cities. We designed a database on drug consumption, obtained by the company that distributes the drugs to the patients. Results: A total of 3,075 patients were studied, with an age mean of 55.8 ± 21.5 years; 50.3% of the participants were women. Of all pa...

show abstract

“…5 Some recent evidence also supports the hypothesis that depressive symptoms are an integral part of schizophrenia. 6,7 Better insight was significantly correlated with lower mood. In addition, it suggests that poor insight may protect against depression in the early stages of recovery from schizophrenia.…”

Section: Introductionmentioning

confidence: 96%

A comparative study of cognitive insight in schizophrenia patients with and without depression

2016

View full text Add to dashboard Cite

Depression in schizophrenia: recognition and management in the USA

Cited by 122 publications

References 30 publications

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: A Novel Dopamine D₂ Receptor Partial Agonist/Serotonin Reuptake Inhibitor with Preclinical Antipsychotic-Like and Antidepressant-Like Activity

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: A Novel Dopamine D₂ Receptor Partial Agonist/Serotonin Reuptake Inhibitor with Preclinical Antipsychotic-Like and Antidepressant-Like Activity

Patrones de prescripción de antipsicóticos en pacientes afiliados al Sistema de Seguridad Social en Salud de Colombia

A comparative study of cognitive insight in schizophrenia patients with and without depression

Contact Info

Product

Resources

About

Depression in schizophrenia: recognition and management in the USA

Cited by 122 publications

References 30 publications

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: A Novel Dopamine D2 Receptor Partial Agonist/Serotonin Reuptake Inhibitor with Preclinical Antipsychotic-Like and Antidepressant-Like Activity

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: A Novel Dopamine D2 Receptor Partial Agonist/Serotonin Reuptake Inhibitor with Preclinical Antipsychotic-Like and Antidepressant-Like Activity

Patrones de prescripción de antipsicóticos en pacientes afiliados al Sistema de Seguridad Social en Salud de Colombia

A comparative study of cognitive insight in schizophrenia patients with and without depression

Contact Info

Product

Resources

About

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: A Novel Dopamine D₂ Receptor Partial Agonist/Serotonin Reuptake Inhibitor with Preclinical Antipsychotic-Like and Antidepressant-Like Activity

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: A Novel Dopamine D₂ Receptor Partial Agonist/Serotonin Reuptake Inhibitor with Preclinical Antipsychotic-Like and Antidepressant-Like Activity